These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
710 related items for PubMed ID: 7653482
1. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Struys A, Snelder AA, Mulder H. Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482 [Abstract] [Full Text] [Related]
2. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate. Watts NB, Becker P. Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786 [Abstract] [Full Text] [Related]
3. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Diamond T, Campbell J, Bryant C, Lynch W. Cancer; 1998 Oct 15; 83(8):1561-6. PubMed ID: 9781950 [Abstract] [Full Text] [Related]
4. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment. Pitt P, Li F, Todd P, Webber D, Pack S, Moniz C. Thorax; 1998 May 15; 53(5):351-6. PubMed ID: 9708225 [Abstract] [Full Text] [Related]
5. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Diamond T, McGuigan L, Barbagallo S, Bryant C. Am J Med; 1995 May 15; 98(5):459-63. PubMed ID: 7733124 [Abstract] [Full Text] [Related]
6. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. Montessori ML, Scheele WH, Netelenbos JC, Kerkhoff JF, Bakker K. Osteoporos Int; 1997 May 15; 7(1):52-8. PubMed ID: 9102064 [Abstract] [Full Text] [Related]
7. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study. Cortet B, Hachulla E, Barton I, Bonvoisin B, Roux C. Rev Rhum Engl Ed; 1999 Apr 15; 66(4):214-9. PubMed ID: 10339777 [Abstract] [Full Text] [Related]
8. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, Di Munno O, Pouillès JM, Horlait S, Cortet B. J Clin Endocrinol Metab; 1998 Apr 15; 83(4):1128-33. PubMed ID: 9543129 [Abstract] [Full Text] [Related]
9. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA. N Engl J Med; 1997 Aug 07; 337(6):382-7. PubMed ID: 9241127 [Abstract] [Full Text] [Related]
10. Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist. Zamberlan N, Castello R, Gatti D, Rossini M, Braga V, Fracassi E, Adami S. Osteoporos Int; 1997 Aug 07; 7(2):133-7. PubMed ID: 9166393 [Abstract] [Full Text] [Related]
11. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. Geusens P, Dequeker J, Vanhoof J, Stalmans R, Boonen S, Joly J, Nijs J, Raus J. Ann Rheum Dis; 1998 Dec 07; 57(12):724-7. PubMed ID: 10070271 [Abstract] [Full Text] [Related]
12. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures. Anderson FH, Francis RM, Bishop JC, Rawlings DJ. Age Ageing; 1997 Sep 07; 26(5):359-65. PubMed ID: 9351480 [Abstract] [Full Text] [Related]
13. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. Jenkins EA, Walker-Bone KE, Wood A, McCrae FC, Cooper C, Cawley MI. Scand J Rheumatol; 1999 Sep 07; 28(3):152-6. PubMed ID: 10380836 [Abstract] [Full Text] [Related]
14. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study. Fogelman I, Herd RJ, Blake GM, Balena R. Calcif Tissue Int; 2000 May 07; 66(5):348-54. PubMed ID: 10773104 [Abstract] [Full Text] [Related]
16. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Lems WF, Jacobs JW, Bijlsma JW, van Veen GJ, Houben HH, Haanen HC, Gerrits MI, van Rijn HJ. Ann Rheum Dis; 1997 Jun 07; 56(6):357-63. PubMed ID: 9227164 [Abstract] [Full Text] [Related]
17. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut CH. Am J Med; 1997 Dec 07; 103(6):468-76. PubMed ID: 9428829 [Abstract] [Full Text] [Related]
18. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy. Fujita T, Satomura A, Hidaka M, Ohsawa I, Endo M, Ohi H. Calcif Tissue Int; 2000 Mar 07; 66(3):195-9. PubMed ID: 10666494 [Abstract] [Full Text] [Related]
20. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. Herd RJ, Balena R, Blake GM, Ryan PJ, Fogelman I. Am J Med; 1997 Aug 07; 103(2):92-9. PubMed ID: 9274891 [Abstract] [Full Text] [Related] Page: [Next] [New Search]